Increased survival of immunodeficient retrovirus infected mice treated with lithium (Meeting abstract).

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Increased survival of immunodeficient retrovirus infected mice treated with lithium (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 35:A1824 1994. Unique Identifier : AIDSLINE ICDB/94603528
Gallicchio VS; Cibull ML; Hughes NK; Tse KF; Hematology and Oncology Division, Department of Internal; Medicine, University of Kentucky Medical Center, Lexington, KY; 40536

Abstract: Murine immunodeficiency virus disease (MAIDS) induced with LP-BM5 MuLV shows many similarities to human HIV-infection. The etiological agent is a defective MuLV capable of inducing disease with the aid of a helper virus. Lithium (Li) influences numerous immunohematopoietic cell types and cellular processes that involve cell proliferation and differentiation. We report here results of in vivo studies investigating the effect of Li in MAIDS. Virus control and Li-treated viral infected C57BL6 mice were monitored for survival and development of MAIDS pathology. Virus-infected mice were grouped to initiate Li (1 mmol) daily as follows: (1) 7-days before virus; (2) 2-days before virus; (3) at the same time as virus, and (4) 5-weeks post-virus inoculation. Daily Li was continued during the study period. Following 36 wk of observation, percent survival was as follows: virus controls, 0%; Li 7-days 100%; Li 2-days 90%; Li day-0 85%; and Li 5 weeks post-virus 80%. Development of lymphoma in Li-treated virus infected mice was reduced significantly as measured via ultrastructural, histopathological and gross anatomical analysis as measured by thymus involvement, lymphadenopathy and splenomegaly (gm): virus control, 1.21 +/- 0.21; Li 5-weeks post-virus, 0.48 +/- 0.03; Li day 0, 0.28 +/- 0.01; Li 2-days, 0.25 +/- 0.02; normal control 0.1 +/- 0.01 (P value less than 0.01). Myeloid, erythroid and megakaryocyte hematopoietic progenitors were also increased compared to virus infected controls. These studies indicate Li is an efficacious treatment in modulating MAIDS and raises important questions regarding its potential role in the pathophysiological processes associated with retroviral infections.

Keywords: Animal Antiviral Agents/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE Drug Administration Schedule Hematopoietic Stem Cells/DRUG EFFECTS/PATHOLOGY Lithium/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE Lymphoma/COMPLICATIONS/PREVENTION & CONTROL Mice Mice, Inbred C57BL Murine Acquired Immunodeficiency Syndrome/COMPLICATIONS/*DRUG THERAPY/PATHOLOGY ABSTRACT
941230
M94C4326

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .